1. Executive Summary |
2. Global Ovarian Cancer Diagnostics Market Introduction |
2.1. Global Ovarian Cancer Diagnostics Market – Taxonomy |
2.2. Global Ovarian Cancer Diagnostics Market –Definitions |
2.2.1. By Diagnosis Type |
2.2.2. By Cancer Type |
2.2.3. By End User |
2.2.4. By Region |
3. Global Ovarian Cancer Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Global Ovarian Cancer Diagnostics Market Dynamic Factors – Impact Analysis |
3.6. Global Ovarian Cancer Diagnostics Market – Competition Landscape |
4. Global Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 |
4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Ovarian Cancer Diagnostics Market, By Diagnosis Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1. Imaging |
5.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Blood Test |
5.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Biopsy |
5.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6. Global Ovarian Cancer Diagnostics Market, By Cancer Type, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1. Epithelial Tumor |
6.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Germ cell Tumor |
6.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Stromal Cell Tumor |
6.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7. Global Ovarian Cancer Diagnostics Market, By End User, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1. Hospital Laboratories |
7.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Cancer Diagnostics Centers |
7.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Research Institutions |
7.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Others |
7.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Ovarian Cancer Diagnostics Market Forecast, By Region, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1. North America |
8.1.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia-Pacific |
8.3.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Latin America |
8.4.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Middle East and Africa |
8.5.1. Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
8.6. Global Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type,By Cancer Type, End User, and Region, 2022 – 2028 |
9. North America Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
9.1. Diagnosis Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.1.1. Imaging |
9.1.2. Blood Test |
9.1.3. Biopsy |
9.1.4. Others |
9.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.2.1. Epithelial Tumor |
9.2.2. Germ Cell Tumor |
9.2.3. Stromal Cell Tumor |
9.2.4. Others |
9.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
9.3.1. Hospital Laboratories |
9.3.2. Cancer Diagnostic Centers |
9.3.3. Research Institutes |
9.3.4. Others |
9.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
9.4.1. USA |
9.4.2. Canada |
9.5. North America Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2022 – 2028 |
9.6. North America Ovarian Cancer Diagnostics Market Dynamics – Trends |
10. Europe Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
10.1. Diagnosis Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.1.1. Imaging |
10.1.2. Blood Test |
10.1.3. Biopsy |
10.1.4. Others |
10.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.2.1. Epithelial Tumor |
10.2.2. Germ Cell Tumor |
10.2.3. Stromal Cell Tumor |
10.2.4. Others |
10.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
10.3.1. Hospital Laboratories |
10.3.2. Cancer Diagnostic Centers |
10.3.3. Research Institutes |
10.3.4. Others |
10.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
10.4.1. Germany |
10.4.2. UK |
10.4.3. France |
10.4.4. Spain |
10.4.5. Italy |
10.4.6. Russia |
10.4.7. Rest of Europe |
10.5. Europe Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2022 – 2028 |
10.6. Europe Ovarian Cancer Diagnostics Market Dynamics – Trends |
11. Asia-Pacific Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
11.1. Diagnosis Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.1.1. Imaging |
11.1.2. Blood Test |
11.1.3. Biopsy |
11.1.4. Others |
11.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.2.1. Epithelial Tumor |
11.2.2. Germ Cell Tumor |
11.2.3. Stromal Cell Tumor |
11.2.4. Others |
11.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
11.3.1. Hospital Laboratories |
11.3.2. Cancer Diagnostic Centers |
11.3.3. Research Institutes |
11.3.4. Others |
11.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
11.4.1. China |
11.4.2. India |
11.4.3. Japan |
11.4.4. ASEAN |
11.4.5. Australia & New Zealand |
11.4.6. Rest of Asia-Pacific |
11.5. Asia-Pacific Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2022 – 2028 |
11.6. Asia-Pacific Ovarian Cancer Diagnostics Market Dynamics – Trends |
12. Latin America Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
12.1. Diagnosis Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.1.1. Imaging |
12.1.2. Blood Test |
12.1.3. Biopsy |
12.1.4. Others |
12.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.2.1. Epithelial Tumor |
12.2.2. Germ Cell Tumor |
12.2.3. Stromal Cell Tumor |
12.2.4. Others |
12.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
12.3.1. Hospital Laboratories |
12.3.2. Cancer Diagnostic Centers |
12.3.3. Research Institutes |
12.3.4. Others |
12.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
12.4.1. Brazil |
12.4.2. Mexico |
12.4.3. Argentina |
12.4.4. Rest of Latin America |
12.5. Latin America Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2022 – 2028 |
12.6. Latin America Ovarian Cancer Diagnostics Market Dynamics – Trends |
13. Middle East and Africa Ovarian Cancer Diagnostics Market Analysis, 2017 – 2021 and Forecast, 2022 – 2028 (Revenue, USD Mn) |
13.1. Diagnosis Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.1.1. Imaging |
13.1.2. Blood Test |
13.1.3. Biopsy |
13.1.4. Others |
13.2. Cancer Type Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.2.1. Epithelial Tumor |
13.2.2. Germ Cell Tumor |
13.2.3. Stromal Cell Tumor |
13.2.4. Others |
13.3. End User Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
13.3.1. Hospital Laboratories |
13.3.2. Cancer Diagnostic Centers |
13.3.3. Research Institutes |
13.3.4. Others |
13.4. Country Analysis 2017 – 2021 and Forecast 2022 – 2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
13.4.1. Gulf Cooperation Council (GCC) Countries |
13.4.2. Israel |
13.4.3. South Africa |
13.4.4. Rest of MEA |
13.5. MEA Ovarian Cancer Diagnostics Market – Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2022 – 2028 |
13.6. MEA Ovarian Cancer Diagnostics Market Dynamics – Trends |
14. Competition Landscape |
14.1. Strategic Dashboard of Top Market Players |
14.2. Company Profiles (Introduction, Financial Analysis, Diagnosis Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
14.2.1. F. Hoffmann-La Roche Ltd |
14.2.2. GlaxoSmithKline plc |
14.2.3. Johnson & Johnson Services Inc |
14.2.4. AstraZeneca plc |
14.2.5. Siemens Healthcare GmbH |
14.2.6. Quest Diagnostics Incorporated |
14.2.7. Thermo Fisher Scientific |
14.2.8. Bio-Rad Technologies Inc. |
14.2.9. Abbott |
15. Research Methodology |
16. Key Assumptions and Acronyms |